Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase [0.03%]
Comfort Kunak Ogar,Malede Mequanent Sisay,Leonardo Roque-Pereira et al.
Comfort Kunak Ogar et al.
Aim: Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine-derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immuniz...
The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom [0.03%]
Simrit Dhillon,Albert A Antolin,Alan M Jones
Simrit Dhillon
Aims: This work aimed to correlate potential links between the suspected adverse drug reaction (ADR) profile of licensed nonsteroidal androgen receptor antagonists (NSARA) with their unique chemical properties and known o...
Yu-Ling Tseng,Chien-Chou Su,Ching-Shiang Yang et al.
Yu-Ling Tseng et al.
Aim: Vancomycin is a cornerstone therapy for severe gram-positive infections but is known to cause acute kidney injury (AKI). Although AKI risk is concentration dependent, its heterogeneous nature in real-world polypharma...
Concentration dependency of an acyl glucuronide metabolite in eltrombopag-induced hepatotoxicity: Role of UGT1A1 genotype [0.03%]
Shun Oda,Kosuke Doki,Naoshi Obara et al.
Shun Oda et al.
Aim: Eltrombopag, a thrombopoietin receptor agonist for aplastic anaemia, can cause hepatotoxicity. It is metabolized by uridine diphosphate-glucuronosyltransferase (UGT) 1A1 to form an acyl glucuronide metabolite; howeve...
Contraindicated drug-drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients [0.03%]
Emilie Laval,Sylvain Goutelle,Inesse Boussaha et al.
Emilie Laval et al.
Background and purpose: Drug-drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequen...
A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11) [0.03%]
Katherine Z Isoardi,Angela L Chiew,Keith Harris et al.
Katherine Z Isoardi et al.
Aim: There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods:...
Mind the gap: Adherence to denosumab dosing and cessation guidelines in Australian residential aged care [0.03%]
Marea O&#x;Donnell,Johanna I Westbrook,Bayzidur Rahman et al.
Marea O&#x;Donnell et al.
Aims: Denosumab and bisphosphonates are the main treatments for osteoporosis in residential aged care (RAC). Strict adherence to 6-monthly denosumab dosing is critical as delayed doses can result in bone resorption and ve...
Global and regional knowledge of antibiotic use and resistance among healthcare students: A systematic review and meta-analysis [0.03%]
Asa Auta,Erick Wesley Hedima,Emmanuel O Adewuyi et al.
Asa Auta et al.
Aims: We synthesized and analysed existing evidence on healthcare students' knowledge of antibiotic use and resistance to provide pooled global and regional estimates. ...
Evaluating the clinical efficacy of combinatorial pharmacogenomic-guided treatment in schizophrenia patients [0.03%]
Jiqing Li,Weili Xia,Ping Fu et al.
Jiqing Li et al.
Aims: This study aims to evaluate the impact of combinatorial pharmacogenomic (CPGx)-guided treatment (CPGT) on medication patterns, symptom remission and hospital stay in patients with schizophrenia. ...